(CercleFinance.com) – Oddo BHF reaffirms its ‘outperform’ opinion on Moderna, but with a price target reduced from 205 to 118 dollars, due to an update of its model in order to take into account short and medium term communicated by management.
If the ‘post-pandemic transition is felt’, the research office underlines that the group still aims to launch 15 new mRNAs in the next five years and to reach between 8 and 15 billion dollars in sales for its respiratory franchise.
According to Oddo BHF, the next launch against the respiratory syncytial virus planned for 2024, that is to say a few months after Pfizer and GSK, ‘should reassure investors who will no longer see Moderna as an essentially Covid 19 player’.
Copyright © 2023 CercleFinance.com. All rights reserved.
The information and analyzes distributed by Cercle Finance only constitute a decision-making aid for investors. Cercle Finance cannot be held responsible directly or indirectly following the use of information and analyzes by readers. It is recommended that any uninformed person consult a professional advisor before making any investment. This indicative information does not in any way constitute an inducement to sell or a solicitation to buy.
Did you like this article ? Share it with your friends using the buttons below.
